In addition, MetS was associated with an overexpression of NOX-4 (p < 0.001), SOD-1 (p < 0.05), and GSR (p < 0.001) that was significantly prevented by CSAT+® treatment (p < 0.001 for all). The gene discussed is NOX4; the disease is metabolic syndrome.